This study is designed to investigate the movement of insulin NNC0363-0845 throughout the body and how it works for the treatment of type 1 diabetes mellitus.
The aim of the study is to improve clinical outcomes for patients with type 1 diabetes mellitus by better controlling the blood sugar levels.
Participants will get insulin NNC0363-0845 as well as insulin detemir (Levemir®). NNC0363-0845 is a new insulin molecule designed to provide blood sugar-dependent insulin action, while insulin detemir is commonly used and prescribed by doctors.
Participants will get subcutaneous (under your skin) injections of insulin NNC0363-0845 (study medicine) up to 6 times daily for 3 days, and of insulin detemir up to 6 times daily for another 3 days. Which medication participants receive first and which second, insulin NNC0363-0845 or insulin detemir, is decided by chance.
The study will last for about 6 weeks up to a maximum of 14 weeks. Participants will have 2 in-house visits (where participants will stay at the site for 4 nights) and 5 outpatient visits with the study doctor. Participants will have frequent contact with the study doctor during the study.
During the in-house visits, two intravenous catheters (a thin tube inserted into a vein) will be inserted for blood sampling and infusions.
Interested parties may not participate in the study if the study doctor believes it will affect their health negatively.
Women cannot take part if they are of childbearing potential.

Start Date01 Dec 2021

Sponsor / Collaborator

Novo Nordisk A/S

NCT03960814

/ CompletedNot Applicable

Retrospective Cohort Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine

This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK). The data for this study will be drawn from the Clinical Practice Research Datalink (CPRD) Register.

Start Date21 May 2019

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with Insulin detemir

100 Translational Medicine associated with Insulin detemir

100 Patents (Medical) associated with Insulin detemir

1,050

Literatures (Medical) associated with Insulin detemir

01 May 2025·The Journal of Prevention of Alzheimer's Disease

Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials

Article

Author: Zhu, Guanghui ; Zhang, Jingjing ; Zhong, Jiaxin ; Cai, Zixin

BACKGROUNDAlzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options. Emerging evidence suggests that antidiabetic agents may offer neuroprotective effects by targeting shared pathophysiological mechanisms such as insulin resistance and neuroinflammation. However, the comparative efficacy, and safety of these agents in the treatment of AD remain unclear.OBJECTIVESThis study aimed to systematically evaluate and compare the efficacy and safety of antidiabetic agents for improving cognitive outcomes, reducing amyloid-β (Aβ) deposition, and managing adverse effects in patients with AD, using a network meta-analysis of randomized controlled trials (RCTs).METHODSA comprehensive literature search was conducted across multiple databases to identify RCTs examining the effects of antidiabetic agents in patients with AD. The primary outcomes included cognitive performance (e.g., MMSE scores), Aβ deposition (measured via CSF biomarkers), and safety/adverse effects. A network meta-analysis was performed to integrate direct and indirect evidence, ranking interventions using Surface Under the Cumulative Ranking (SUCRA) probabilities. Risk of bias was assessed using the Cochrane risk-of-bias tool.RESULTSA total of 26 studies, involving 7,361 participants, were included in the analysis. The interventions evaluated included insulin detemir (both low-dose and high-dose), liraglutide, exenatide, metformin, and pioglitazone. Both low-dose insulin detemir (mean difference: 2.10, 95 % CI: 1.04 to 3.15), high-dose insulin detemir (mean difference: 1.40, 95 % CI: -0.07 to 2.88), exenatide (mean difference: 1.19, 95 % CI: 0.06 to 2.32), and metformin combined with exenatide (mean difference: 1.06, 95 % CI: -1.68 to 3.80) showed cognitive improvements compared to placebo. Among these, low-dose insulin detemir demonstrated the most significant improvement. In terms of reducing Aβ deposition, metformin ranked highest in effectiveness, with the highest SUCRA score (84.6), followed by high-dose insulin detemir (SUCRA: 54.1). Low-dose insulin detemir (SUCRA: 51.1) also demonstrated moderate efficacy. Low-dose insulin detemir showed some reduction in Aβ deposition (mean difference: -0.31, 95 % CI: -2.82 to 2.20), although statistical significance was limited. Liraglutide exhibited the highest rate of study treatment withdrawal (mean difference: 1.97, 95 % CI: -0.07 to 4.00), while pioglitazone demonstrated the lowest withdrawal rates (mean difference: 0.07, 95 % CI: -0.03 to 0.17).CONCLUSIONSThis network meta-analysis provides valuable insights into the comparative efficacy and safety of antidiabetic agents in AD. Low-dose insulin detemir demonstrated the most significant cognitive improvement and a moderate effect on reducing Aβ deposition. Metformin emerged as the most effective agent for reducing Aβ levels, though its effects on cognitive function were less pronounced. Safety profiles varied, with liraglutide associated with the highest rate of treatment withdrawals, while pioglitazone demonstrated the lowest incidence of treatment-related discontinuations. These findings support the potential use of antidiabetic agents, particularly insulin detemir, as a therapeutic option for AD, although further studies are needed to confirm their long-term benefits and safety.

01 May 2025·Value in Health Regional Issues

Cost-Effectiveness Analysis of Pharmacological Treatment With Insulin and Insulin Analogs for Type 1 and Type 2 Diabetes Mellitus in Colombia

Article

Author: Plazas, Merideidy ; Morales, Christian Camilo Anzola ; Arango, Luz Karime Osorio ; Escobar, Ivan Darío ; Ramirez, Luis Esteban Orozco ; Ibáñez, Diego Fernando Ávila

OBJECTIVESThis study aimed to estimate the cost-effectiveness relationship of insulins and insulin analogs in diabetes mellitus type 1 (DM1) and 2 (DM2), from the perspective of the Colombian health system.METHODSA short-term decision tree model (SM) was built, the outcome of which was severe/nocturnal hypoglycemia, and a long-term Markov model for quality-adjusted life-years. The probabilities were calculated through a literature review of effectiveness and safety. The costs are estimated from official databases. Deterministic and probabilistic sensitivity analyses were performed.RESULTSFor DM1, in prandial insulins, and for both models, the cost-effective interventions (CEIs) are aspartate and lispro. In basal insulins, the CEIs are NPH and glargine U-100 in both models. In the comparison of detemir and NPH, detemir generates lower nocturnal hypoglycemia and higher quality-adjusted life-years; however, in the long-term Markov model, the incremental cost-effectiveness ratio exceeds the threshold. For DM2, in the prandial insulin, and for both models, aspartate is a CEI and the glargine U-300 is also a CEI in the SM. In basal insulin, the CEIs are glargine U-100 and detemir (for nocturnal hypoglycemia) in both models and glargine U-300 is also a CEI in the SM. Finally, in the group of combinations, iGlarLixi is dominant over IDegLira.CONCLUSIONSThe results favor the use of analog insulins over human insulins, the former reducing the possibility of acute events and chronic complications to a greater extent.

01 Mar 2025·Endocrinología, Diabetes y Nutrición (English ed.)

Hyperglycemia-related risk factors in enteral nutrition in non-critically ill patients

Article

Author: Gómez-Hoyos, Emilia ; Ortolá-Buigues, Ana ; Delgado-García, Esther ; Torres-Torres, Beatriz ; López-Gómez, Juan José ; Pérez-López, Paloma ; Jiménez-Sahagún, Rebeca ; De Luis-Román, Daniel A

INTRODUCTIONCarbohydrate metabolism can change in hospitalized patients due to stress, or the use of enteral nutrition (EN). The aim of this study was to determine the risk factors triggering these changes.MATERIAL AND METHODSWe conducted a retrospective observational study in non-diabetic patients with low levels of stress on EN. Five groups were categorized based on changes to the metabolism of hydrocarbons produced before or after EN: plasma glycemia prior to EN >126mg/dL (stress hyperglycemia - SH) (35.1%); plasma glycaemia prior to EN <126mg/dL (non-HE) (64.89%). Hyperglycemia with EN (HyperEN): at least, two capillary blood glucose readings >140mg/dL or 1 >180mg/dL during EN (71%); non-HyperEN: capillary blood glucose readings with EN <140mg/dL (29%).RESULTSA total of 131 patients were included (45.8% men) with a median age of 81 (71-87) years. A total of 52 patients exceeded 180mg/dL at one measurement, and 24 patients required insulin detemir with a median of 16 (12-27) IU per day. Risk factors for HyperEN were identified as patient age (OR, 1.186; 95% CI, 1.051-1.341; p<0.01) and duration of nutritional treatment (OR, 1.320; 95% CI, 1.086-1.605; p<0.01).CONCLUSIONSOur study shows a high prevalence of carbohydrate metabolism disorders in hospitalized patients on total EN, with age and duration of nutritional treatment being the main risk factors.

News (Medical) associated with Insulin detemir

05 Apr 2025

·endpts.com

Q&A: A conversation with GLP-1 co-discoverer Jens Juul Holst on the future of incretin-based drugs

Medicines based on glucagon-like peptide-1 (GLP-1) have revolutionized the treatment of diabetes and obesity. On Saturday, five scientists involved in the discovery and characterization of the peptide and its translation into therapeutic drugs were awarded one of the $3 million Breakthrough Prizes in Life Sciences, an award sometimes considered a precursor to a Nobel Prize. The five winners are: Svetlana Mojsov of The Rockefeller University; Lotte Bjerre Knudsen of Novo Nordisk; Jens Juul Holst of the Novo Nordisk Foundation Center for Basic Metabolic Research and the University of Copenhagen; Daniel Drucker of the University of Toronto and Sinai Health; and Joel Habener of Harvard University. Ahead of the announcement, Endpoints News spoke with Holst, the co-discoverer of GLP-1, about his career so far, and about future work. The conversation has been substantially edited for length and clarity. Another Breakthrough Prize went to the gene editing pioneer David Liu, who spoke with Endpoints’ Ryan Cross. Elizabeth Cairns : Congratulations! How does it feel to get this recognition? Jens Juul Holst : To tell you the truth, I didn’t know much about the Breakthrough Prize until I was notified some months ago. They forced me to wear black tie, which is something that I never have worn before. So it’s a bit of a surprise all the way through. Cairns : At least you’ve had a little while to get used to it. Are you proud? Holst : I’m extremely happy about these awards, not for my personal satisfaction, but because of the general appreciation of the work we’ve done. I’m a medical doctor and it’s fantastic to see these incredible results coming up in front of my eyes. It was something we hoped for, of course, but it was completely unpredictable many years ago when we uncovered this hormone. Cairns : You discovered GLP-1 in 1986. Did you realize how significant it was going to be? Holst : No. We found this insulin-releasing peptide, but there were many insulin-releasing peptides from the gut. Eventually we found out that it was the peptide that was responsible for low glucose levels in some of the patients we were helping. It turned out that compared to all the other insulin-releasing peptides, it did something else: It also inhibited glucagon secretion. That was really something. And we found that it was a very strong inhibitor of gastric emptying, and also intestinal transit. We also found that it was a neural mechanism, which turned our attention to the brain. Because this was a gut hormone and we knew that the gut would play a role in the regulation of food intake and appetite, we also looked at that, and sure enough, it also inhibited appetite. Cairns : How long did it take you to get from the discovery of the peptide to initial human research? Holst : That key step was in 1993, so it took quite some time. Cairns : What were the challenges you faced? Holst : That’s simple: money. Like most researchers we were relying on external support for our research, and throughout the early years, we were really short of support, forcing us to use old-fashioned, secondhand equipment and cheapest possible reagents, etc., and wages were kept at a minimum. But we got by, collaborating with friends who had been lucky to get better equipment. Cairns : Why do you think this recognition is coming now? Holst : That has to do with a development that nobody could have foreseen. That is the tremendous weight loss that the higher doses of the modern, long-acting agonists had. The effect on food intake was recognized early on. The question was how to harness this without having too many problems with side effects. People were brave. “OK, if we slowly up titrate, then maybe we can get to higher doses and get a greater weight loss.” And that was published in 2009 in The Lancet . That led to the approval of liraglutide [Saxenda] for obesity. This was a sensation. And in the meantime, a second generation GLP-1 had been launched for diabetes, and that was semaglutide [Ozempic/Wegovy]. I was there when it was developed. The weight loss was, again, something like 8%. Nothing sensational about that. But people did a new dose-response study this time with very small daily doses, and it turned out that you could get as high as something like 0.4 milligrams per day, and that would result in a 15% weight loss. And then the world went crazy. Cairns : It did indeed. This prize has been split five ways — were you all working in separate groups towards a similar end? Holst : Completely separately, yes. Although Lotte Bjerre, the chemist, she was a kind of a partner with me, we knew each other very well. What she did was to create liraglutide on the basis of the long-acting insulins Novo Nordisk was doing in those days. They were doing insulin detemir, which is long-acting because they attached the fatty acid to the molecule. She did that as well to GLP-1, and it worked. So she was responsible for the liraglutide part of it. Cairns : Where do you think research in this field might or should go in the future? Holst : People that are prescribed a GLP-1 agonist do not stay on therapy. One of the ways whereby GLP-1 agonists inhibit food intake is by inhibiting the reward mechanism, and this is very important because that is the same mechanism that is responsible for its effects on addiction — alcohol, opioids. Apparently there are fantastic effects on this. But the reward system also takes away some of the pleasure of eating. This is something that should be looked at in detail. Maybe it’s not fun to be on a GLP-1 receptor agonist. If your greatest pleasure in life is to eat good meals and that pleasure is taken away from you, what is left? In the meantime, there are other major problems to look at. One is to provide sufficient amounts of the GLP-1s, and get them to affordable prices. But they will be solved, there’s no doubt about that. There’ll be lots of producers of them, and that means that the prices will really fall and there will also be more products. Cairns : Are prizes like this becoming more important as a source of funding for this kind of research, especially with cuts to agencies like the NIH in the US? Holst : That’s a sneaky question because in principle, they’re personal, those prizes. I mean, it’s my money. Cairns : Yeah, absolutely. Sorry. Holst : I actually wanted to transfer some of the money for research, and it turned out that the part I wanted to transfer for research is being taxed. So it was quite expensive for me to transfer money for research from my personal prize. And frankly, the family didn’t think it was a good idea. They wanted the money. Cairns : So would I, I have to say. What do you intend to do with the money you’re keeping? Are you going to have a holiday, buy a car? Holst : A holiday? Christ, what is that? No. We have work to do. Cairns : The Breakthrough Prize is sometimes thought of as a harbinger for the Nobel. Do you think that GLP-1 research might win a Nobel in the future? Holst : They don’t apparently accept more than three recipients. That precludes a Nobel Prize for all the five of us. The scientific advance made by GLP-1 is big enough and suitable for the regulations of the Nobel Prize. But I have absolutely no idea what they’re going to think of in Stockholm. And it’s good enough as it is already. Cairns : If you do win, they’ll make you wear black tie again. Holst : Not even black tie, but white tie. It would be even worse!

05 Mar 2025

·www.biospace.com

Novo, Sanofi Hit With Anti-Competitive Probe in South Africa:

iStock, valiantsin suprunovich The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to lower drug prices. The South African government is investigating alleged anti-competitive practices by Novo Nordisk and Sanofi in connection with human insulin pens, Bloomberg reported on Monday evening. The Competition Commission of South Africa, the government’s anti-trust agency, is scrutinizing the companies’ device patents and proprietary designs to determine if these are being exploited to limit competition and block the entry of other developers and suppliers, as per Bloomberg. The watchdog is currently in the process of coordinating with Novo Nordisk’s and Sanofi’s local entities. BioSpace has reached out to Sanofi and Novo Nordisk for their statements and will update this article accordingly. The insulin market has seen some heavy upheaval over the last few years, driven by key policy changes around the world. Chief among these is the Inflation Reduction Act, signed into law in August 2022, and the Affordable Insulin Now Act, both of which seek to dramatically minimize Americans’ out-of-pocket spending for insulins. Pressure from lawmakers have also helped lower insulin prices in the U.S. The Competition Commission’s investigation comes shortly after it fined Google about $30 million per year for the next five years, while also investigating Meta and the social media network X (formerly Twitter), all for business practices that harmed South African media. Eli Lilly in March 2023 announced that it would lower insulin prices by 70% and cap out-of-pocket costs at $35 per month. Novo and Sanofi followed suit soon after, enacting their respective price cuts in the subsequent weeks. Months later, however, Novo announced that it would discontinue its long-acting insulin product Levemir, removing both the vials and pen from the market by the end of 2024. Lilly in Mach 2024 announced that due to marketing constraints, availability of two of its inulin products—Humalog an Lispro— would be limited . Sanofi also discontinued its pre-mixed insulin product Insuman, though this move mostly affected the U.K. and came in February 2023, a month before it announced the insulin price cuts. In a May 2024 interview with BioSpace , BMO Capital Markets analyst Evan Seigerman said that Novo “can’t make a product they’re losing money on, which may be the case with some insulins, and at some point they need to be smart with capital.” Still, the drugmakers continue to innovate on insulins. Lilly, for instance, is advancing a once-weekly insulin injection, Phase III readouts for which showed it could lower A1C by 1.34% , as compared with the 1.26% reduction for once-daily insulin degludec. Novo is also working on its own once-weekly product, dubbed insulin icodec. In July 2024, however, the program hit a regulatory road bump when the FDA rejected its drug application, flagging issues with the use of the product in type 1 diabetes.

Phase 3

06 Feb 2025

·www.echemi.com

Novo Nordisk Reports 2024 Earnings with $42.13 Billion Revenue and Impressive Profit Margins

On February 5, Novo Nordisk officially released its annual report for 2024, revealing a remarkable revenue of 29.04 billion Danish kroner (approximately $42.13 billion), representing a 25% increase year-on-year. The operating profit also surged to 12.83 billion Danish kroner (around $18.62 billion), reflecting a 25% growth, while net profit reached 10.10 billion Danish kroner (about $14.65 billion), up 21%. Notably, Novo Nordisk's profit margin (operating profit/sales) stands at an impressive 44.19%, far surpassing many American pharmaceutical giants. Novo Nordisk operates primarily in two business segments: Diabetes and Obesity Care and Rare Diseases. The majority of its revenue comes from the Diabetes and Obesity Care segment, which generated 27.18 billion Danish kroner in sales for 2024, while the Rare Diseases segment contributed only 1.86 billion Danish kroner. The GLP-1 class of drugs has emerged as Novo Nordisk's biggest revenue driver. Rybelsus (oral semaglutide) achieved sales of 23.30 billion Danish kroner (approximately $3.38 billion), while Ozempic (injectable semaglutide) brought in 120.34 billion Danish kroner (around $17.46 billion). The weight-loss version, Wegovy, also performed well with sales of 58.21 billion Danish kroner (about $8.44 billion). The total sales for semaglutide reached $29.28 billion, showcasing its strong performance, although it has not yet dethroned Keytruda as the new king of drugs. In addition to semaglutide, Novo Nordisk's GLP-1 offerings include the previous generation liraglutide, with Victoza (liraglutide for diabetes) and Saxenda (liraglutide for weight loss) generating 5.48 billion Danish kroner (approximately $795 million) and 6.94 billion Danish kroner (around $1.01 billion), respectively. Insulin remains Novo Nordisk's second-largest revenue generator, with total sales of 55.37 billion Danish kroner (approximately $8.03 billion) in 2024, driven by the success of degludec insulin, which saw a 15.3% increase in sales compared to the previous year. The three long-acting insulins—Tresiba (degludec), Xultophy (degludec/liraglutide), and Levemir (detemir)—achieved sales of 9.91 billion, 4.67 billion, and 4.50 billion Danish kroner, respectively. The two premixed insulins, Ryzodeg (degludec/aspart) and NovoMix (premixed aspart), generated revenues of 4.93 billion and 5.86 billion Danish kroner, respectively, with the former showing growth while the latter declined. Rapid-acting insulins, including Fiasp (ultra-rapid aspart) and NovoRapid (aspart), collectively sold 18.52 billion Danish kroner, an increase of approximately 2.6 billion compared to the previous year. Additionally, Novo Nordisk continues to sell second-generation human insulin, which generated 6.97 billion Danish kroner, although this segment saw a year-on-year decline. In the Rare Diseases segment, Novo Nordisk's product pipeline primarily includes clotting factors and growth hormones, with total sales of only 1.86 billion Danish kroner, representing a small portion of overall revenue. Unlike other major international pharmaceutical companies, Novo Nordisk has not pursued large-scale acquisitions and maintains a research and development investment intensity of around 15%. However, the company's sustained high revenue growth demonstrates its efficiency in product development. This efficiency can be attributed to four key factors: a strong focus on diabetes, extensive knowledge accumulation over a century, a commitment to user experience, maximizing market value from existing products, and the development of platform technologies. With advanced fatty acid acylation technology, peptide oral delivery technology, and yeast fermentation technology, Novo Nordisk is well-positioned to maintain its competitive edge in the market.

AcquisitionFinancial StatementDrug ApprovalBiosimilar

100 Deals associated with Insulin detemir

External Link

KEGG	Wiki	ATC	Drug Bank
D04539	Insulin detemir	A10AE05	DB01307

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	United States	Novo Nordisk A/S	19 Oct 2005
Diabetes Mellitus, Type 2	United States	Novo Nordisk A/S	19 Oct 2005
Diabetes Mellitus	Norway	Novo Nordisk A/S	01 Jun 2004
Diabetes Mellitus	Iceland	Novo Nordisk A/S	01 Jun 2004
Diabetes Mellitus	Liechtenstein	Novo Nordisk A/S	01 Jun 2004
Diabetes Mellitus	European Union	Novo Nordisk A/S	01 Jun 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Preclinical	Finland	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Preclinical	France	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Preclinical	Sweden	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Preclinical	Australia	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Preclinical	Netherlands	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Preclinical	Ireland	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Preclinical	Denmark	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Preclinical	Norway	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Preclinical	Belgium	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Preclinical	United Kingdom	Novo Nordisk A/S	01 Feb 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01186003 (CTgov)	Not Applicable	Diabetes Mellitus	30	insulin+detemir (Standard Insulin Drip Therapy)	izvfzidtft(emivekzcbg) = ukxfzauzon myqywfnulh (jpybvotyjl, mmvqqjanjb - mldvvggdyj) View more	-	07 Dec 2021
				Detemir (Insulin Drip and Detemir)	izvfzidtft(emivekzcbg) = jqehylncqp myqywfnulh (jpybvotyjl, xpvvjtfdxp - nrrkdumrzo) View more
NCT03377699 (EXPECT, EASD2021)	Phase 3	Diabetes Mellitus, Type 1	225	Degludec	(udjeigrdeh) = xogzabmzxd oycovhjzar (tcungalryf, -0.11)	Positive	28 Sep 2021
				Detemir	(udjeigrdeh) = tenmylftwn oycovhjzar (tcungalryf )
NCT03620890 (Determin, CTgov)	Phase 4	Diabetes Mellitus, Type 2	108	Detemir insulin (Detemir)	akiksovncu(rgsfmengni) = nqstyqwezh pjfewpsrue (xxprkoyqns, pimxsokify - mkfiqgdtaa) View more	-	18 Aug 2021
				Neutral Protamine Hagedorn (NPH) (Neutral Protamine Hagedorn (NPH))	akiksovncu(rgsfmengni) = azzjkgjsnd pjfewpsrue (xxprkoyqns, gdfnnbjabl - eyjymvappb) View more
NCT02846233 (CTgov)	Not Applicable	Diabetes Mellitus, Type 2	22	SGLT2 inhibitor+levemir+Lantus+Metformin (Treatment Group)	fkxlmioxcq(valvmlacos) = bxmoixkelw nvsukhyzmt (rsplxlduix, euqxjriweu - ccjptowpsp) View more	-	10 Nov 2020
				SGLT2i (Control Group)	fkxlmioxcq(valvmlacos) = vdtbnxlwbe nvsukhyzmt (rsplxlduix, gvnebwywgz - cygvunvfpl) View more
NCT01966978 (SIMPLE, CTgov)	Phase 4	Diabetes Mellitus, Type 2	157	Insulin Aspart+Detemir+Metformin (Control: Metformin, Insulin Detemir, Insulin Aspart)	fpscsxprlm(lgkklywqvp) = mspgojqswi bztcnczjvy (vrlglibrcm, tsueelopgt - bnmmtlucsj) View more	-	22 Oct 2019
				Detemir+liraglutide+Metformin (Metformin, Insulin Determir, Liraglutide)	fpscsxprlm(lgkklywqvp) = ufupuuovob bztcnczjvy (vrlglibrcm, rkosxzapms - iouzndttvo) View more
NCT00564018 (CTgov)	Not Applicable	Diabetes Mellitus, Type 1	33	Insulin detemir (Detemir)	gkvszfwdux(pcvawyjcum) = wkqrvpagva jtjhrrronz (mqfgcmyjwf, nnpbnefnri - xbzxftthuh) View more	-	11 Oct 2019
				glargine (Glargine)	gkvszfwdux(pcvawyjcum) = vrzrpmmmky jtjhrrronz (mqfgcmyjwf, abxwalwarr - hyhdawsuql) View more
NCT01232946 (CTgov)	Not Applicable	Diabetes Mellitus, Type 2	30	liraglutide (Iiraglutide)	bhstrcstbl(tykqanhoyw) = unrrmcgcla gmkzdriksf (uaadqqdmzd, xukrsyggkq - bsdkqswspg) View more	-	07 Aug 2019
				Insulin detemir (Insulin Detemir)	bhstrcstbl(tykqanhoyw) = auezvcxlyp gmkzdriksf (uaadqqdmzd, wtubopjgpv - fjasrjbyac) View more
NCT00639626 (CTgov)	Phase 2/3	Cystic fibrosis related diabetes	6	insulin detemir [rDNA origin] injection	wfzegadgxh(pbjfdhcpbq) = tujmgqdjui mfcorvjwxr (kcapdygcoj, atdztusrvw - yrvozjeyka) View more	-	12 Apr 2018
NCT01595646 (SL120, CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	37	Saline (Saline)	nhzpvgezyf(ypuemwqsqu) = ottiognhto qpegylragn (bqiuobnzyx, vdlxwfxhuf - dpsbqvelwu) View more	-	01 Feb 2018
				Insulin detemir (Insulin Detemir)	nhzpvgezyf(ypuemwqsqu) = ssrsitrvpr qpegylragn (bqiuobnzyx, yqwxigmzdi - hlvwrjdrtr) View more
NCT01831765 (onset® 1 \| onset ® 1 \| onset 1, CTgov)	Phase 3	Diabetes Mellitus, Type 1	1,290	insulin detemir+aspart (Faster Aspart (Meal))	nviiaglwdj(dseznuyhub) = tkemaaocex lqjrqjspma (cunzmsqlez, npfivcfzdv - pigozpgxlh) View more	-	23 Jan 2018
				insulin detemir+faster aspart (Faster Aspart (Post))	nviiaglwdj(dseznuyhub) = ptaxtjmjjt lqjrqjspma (cunzmsqlez, dixrjquoqi - mdxuzajrxs) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis